Safety study of fedratinib in Korean patients with myelofibrosis
Part of Blood & lymphatic clinical trials.
This study looks at the safety of the drug fedratinib in Korean patients with myelofibrosis. It will help doctors better understand how well patients tolerate the drug when it's used as approved.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years of age or older
- You have been prescribed fedratinib by your doctor for a use that is approved in Korea
- You are willing to sign a consent form agreeing to take part
- Your use of fedratinib must follow the approved instructions (dose and indication) as per Korean health authorities
- You must not have any medical condition that makes taking fedratinib unsafe for you, as per the approved prescribing information
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called revumenib, either alone or combined with a JAK inhibitor, for people with myelofibrosis that is still active despite standard treatment. The goal is to see if revumenib can better control symptoms, reduce spleen size, or improve blood counts.
This study follows people with myelofibrosis and anemia who are starting a new treatment. It aims to learn more about the disease and how treatments work in real life.
This study uses a new type of PET/CT scan with a tracer called 68Ga-FAPI to help diagnose myelofibrosis, see how advanced it is, and check if treatment is working. It may help doctors better understand your condition and plan your care.
This study tests a combination of two drugs, momelotinib and luspatercept, for people with myelofibrosis who need regular red blood cell transfusions. The goal is to see if the combination can reduce transfusion needs and improve symptoms.
This study follows patients with myelofibrosis (a type of bone marrow cancer) who are already taking or have taken ruxolitinib. Researchers will review medical records to understand how well the medicine works in everyday practice.
This study is checking the safety of a drug called Luspatercept (brand name Reblozyl) for people in Korea who have myelodysplastic syndrome (a blood disorder) or beta-thalassemia (a type of inherited anemia). It is designed to monitor how safe the drug is when used as prescribed by your doctor.
Hear when a new Primary Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.